2026 MIPS Improvement Activity IA_PSPA_31: Patient Medication Risk Education
Written by Tucker Deyett, Dedicated Advisor, ReportingMD. Source data: CMS Quality Payment Program 2026 measure specifications and benchmark files.
Subcategory: Patient Safety and Practice Assessment
At a glance
IA_PSPA_31, Patient Medication Risk Education, is a 2026 MIPS improvement activity in the Patient Safety and Practice Assessment subcategory. For PY2026 activities are not weighted: clinicians with small practice, rural, non-patient-facing, or HPSA status attest to one activity, all other Traditional MIPS participants attest to two, and MVP participants attest to one.
Activity description
In order to receive credit for this activity, MIPS eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. Education must be completed for at least 75% of qualifying patients and occur: (1) at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or (2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.
Activity details
- Activity ID: IA_PSPA_31
- Subcategory: Patient Safety and Practice Assessment
- Programs: Traditional MIPS, APP, APP Plus
- First performance year: 2019
Need help with IA_PSPA_31?
ReportingMD is a CMS qualified registry and healthcare data pipe with a 100% submission rate since 2001. We confirm IA attestations and documentation with every client before submission. Talk to a ReportingMD advisor or browse the full 2026 MIPS directory.